Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2006

01-03-2006 | Original Article

Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis

Authors: S. Andereya, N. Streich, B. Schmidt-Rohlfing, T. Mumme, R. Müller-Rath, U. Schneider

Published in: Rheumatology International | Issue 5/2006

Login to get access

Abstract

Numerous studies have focused on the significance of modern marker proteins in the synovial fluid of the knee joint and in the serum both, for osteoarthritis (OA) and rheumatoid arthritis (RA). The relationship between the serum concentrations and the concentrations in the synovial fluid is still unclear. Synovial fluid and serum samples were obtained from 13 patients with advanced OA and from 8 patients with severe RA and concentrations of MMP-1, MMP-3, MMP-13, TIMP-1, COMP and MIA/CD-RAP were determined. All values were normalized against the total protein concentrations. Serum concentrations of MMP-13 in the RA-group were statistically higher than the synovial values (P<0.05). MMP-13 was the only marker protein that revealed distinct higher levels in the serum than in the synovial fluid. The study design allows only conclusions about advanced stages of RA and OA. Longitudinal investigations may provide further information about the value of MMP-13 as a potential marker to monitor the course of RA and OA.
Literature
1.
Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–461PubMedCrossRef
2.
Firestein GS (1996) Etiology and pathogenesis of rheumatoid arthritis. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) The textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 851–897
3.
Nagase H, Okada Y (1995) Proteinases and matrix degradation. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) The textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 323–341
4.
Nagase H, Woessner JF Jr (1993) Role of endogenous proteinases in the degradation of cartilage matrix. In: Woessner JF Jr, Howell DS (eds) Joint cartilage degradation. Marcel Dekker, New York, pp 159–185
5.
Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE (1996) Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271:30375–30380PubMedCrossRef
6.
Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed
7.
Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C (1994) Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091–2094PubMed
8.
Neidel J, Schulze M, Sova L, Lindschau J (1996) Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis. Z Orthop Ihre Grenzgeb 134:381–385PubMedCrossRef
9.
MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI (1990) Discoordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergetic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238–17245PubMed
10.
Martell Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP (1994) Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthrosis and rheumatoid arthritis. Lab Invest 70:807–815
11.
Mauviel A (1993) Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53:288–295PubMedCrossRef
12.
Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE (1993) The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP) and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 36:372–379PubMedCrossRef
13.
Shinmei M, Kobayashi T, Yoshihara Y, Samura A (1995) Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. J Rheumatol Suppl 43:78–81PubMed
14.
Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969–975PubMedCrossRef
15.
Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583–591PubMedCrossRef
16.
Marti C, Neidhart M, Gerber T, Hauser N, Michel BA, Hauselmann HJ (1999) Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis. Z Rheumatol 58:79–87PubMedCrossRef
17.
Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K (2002) Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10:707–713PubMedCrossRef
18.
Bosserhoff AK, Buettner R (2002) Expression, function and clinical relevance of MIA (melanoma inhibiting activity). Histol Histopathol 17:289–300PubMed
19.
Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W., Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153PubMed
20.
Wagner V, Rudi J, Naher H, Stremmel W (2000) Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Med Oncol 17:35–38PubMedCrossRef
21.
Müller-Ladner U, Bosserhoff AK, Dreher K, Hein R, Neidhart M, Gay S, Scholmerich J, Buettner R, Lang B (1999) MIA (melanoma inhibitory activity): a potentional serum marker for rheumatoid arthritis. Rheumatology 38:148–154PubMedCrossRef
22.
Schmidt-Rohlfing B, Schneider U, Thomsen M, Bosserhoff AK (2002) Correlation of a novel matrix protein with the degree of cartilage degradation. Rheumatol Int 22:165–169PubMedCrossRef
23.
Lohmander LS, Dahlberg L, Ryd L, Heinegard D (1989) Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 32:1434–1442PubMedCrossRef
24.
Schmidt-Rohlfing B, Gavenis K, Kippels M, Schneider U (2002) New potential markers for cartilage degradation of the knee joint. Scand J Rheumatol 31:151–157PubMedCrossRef
25.
Väätäinen U, Lohmander LS, Thonar E, Hongisto T, Agren U, Rönkkö S, Jaroma H, Kosma VM, Tammi M, Kiviranta I (1998) Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patella. Osteoarthritis Cartilage 6:115–124PubMedCrossRef
26.
Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L (2001) Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 44:2777–2789PubMedCrossRef
27.
Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T (2002) Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 46:2648–2657PubMedCrossRef
28.
Bluteau G, Conrozier T, Mathieu P, Vignon E, Herbage D, Mallein-Gerin F (2001) Matrix metalloproteinase-1, −3, −13 and aggrecanase-1 and −2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta 1526:147–158PubMed
29.
Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B (2001) Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum 44:2263–2274PubMedCrossRef
30.
Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR (2001) Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 44:2503–2511PubMedCrossRef
31.
Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2002) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology (Oxford) 41:78–87CrossRef
32.
Bramono DS, Richmond JC, Weitzel PP, Kaplan DL, Altman GH (2004) Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res 428:272–285PubMedCrossRef
33.
Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geohegan KF, Hambor JE (1996) Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. Clin Invest 97:761–768
34.
Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C (1997) Matrix metalloproteinase 13 (Collagenase 3) in human rheumatoid synovium. Arthritis Rheum 40:1391–1399PubMedCrossRef
35.
Gay S, Gay RE, Koopman WJ (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction. Ann Rheum Dis 52:839–847CrossRef
36.
Gay S, Gay RE (1989) Cellular basis and oncogene expression of rheumatoid joint destruction. Rheumatol Int 9:105–113PubMed
37.
Zvaifler NJ, Tsai V, Alsalameh S, von Kempis J, Firestein G, Lotz M (1997) Pannocytes: distinctive cells found in rheumatoid arthritis cartilage erosions. Am J Pathol 150:1125–1138PubMed
Metadata
Title
Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis
Authors
S. Andereya
N. Streich
B. Schmidt-Rohlfing
T. Mumme
R. Müller-Rath
U. Schneider
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0006-2

Other articles of this Issue 5/2006

Rheumatology International 5/2006 Go to the issue

Original Article

Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus

Case Report

Nocardiosis in a patient with primary anti-phospholipid syndrome

Original Article

HgCl2 challenge in Brown Norway rats lead to dermatitis instead of arthritis

Review

Scleroderma associated with ANCA-associated vasculitis

Original Article

Dysautonomia in fibromyalgia syndrome: sympathetic skin responses and RR Interval analysis

Original Article

Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits